Cipla announced that the United States Food and Drug Administration (USFDA) classified the inspection of its manufacturing facility in Verna, Goa as voluntary action indicated (VAI). The company informed exchanges on Thursday, June 11 that it received the communication from the USFDA on June 10, following a routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI) conducted at the facility between April 6 and April 17, 2026. The VAI status is generally considered less severe than an Official Action Indicated (OAI) classification, which can lead to regulatory actions, while being more serious than a No Action Indicated (NAI) classification, where no significant observations are found. As per the latest reports, a VAI classification means the regulator found objectionable conditions but is not expected to take or recommend enforcement action.
Cipla is a global pharmaceutical company with operations across India, South Africa, North America and other regulated and emerging markets. The company focuses on complex generics and therapies including respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. The drug major operates 46 manufacturing facilities globally, producing more than 1,500 products across over 80 markets. The Goa facility is one of Cipla's key manufacturing sites, catering to multiple markets, including the United States. The pharma company's Chief Executive Officer, Achin Gupta, recently told CNBC-TV18 that it is aiming to derive 10% of its revenue from innovation-led products over the next five years as the drugmaker looks to build new growth engines beyond its core generics business.
For the March quarter, Cipla reported a 54.6% fall in its net profit to ₹554.6 crore from the corresponding quarter last year. EBITDA dropped 38% year-on-year to ₹955 crore. Adjusted for the impairment cost, Cipla's EBITDA would be ₹997 crore, largely in line with expectations, and margins would be 15.2%, also in line with the 15.3% projection. However, including impairment, Cipla's EBITDA margin stood at 14.6%, down from 22.8% last year. The stock counter rose 0.6% to ₹1,385.50 on Thursday, following the USFDA announcement. The stock has gained over 6% in the last month, while delivering a negative 9% return over the past 12 months.
